ID: ALA3360415

Max Phase: Preclinical

Molecular Formula: C20H24N6O3

Molecular Weight: 396.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(NC(=O)[C@@H](C)Nc2nc3c(cnn3C3CCCC3)c(=O)[nH]2)cc1

Standard InChI:  InChI=1S/C20H24N6O3/c1-12(18(27)23-13-7-9-15(29-2)10-8-13)22-20-24-17-16(19(28)25-20)11-21-26(17)14-5-3-4-6-14/h7-12,14H,3-6H2,1-2H3,(H,23,27)(H2,22,24,25,28)/t12-/m1/s1

Standard InChI Key:  UBBCZBKJYNXHGT-GFCCVEGCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 396.45

Molecular Weight (Monoisotopic): 396.1910

AlogP: 2.68

#Rotatable Bonds: 6

Polar Surface Area: 113.93

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.56

CX Basic pKa: 1.48

CX LogP: 1.97

CX LogD: 1.97

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.59

Np Likeness Score: -1.54

References

1. Shao YX, Huang M, Cui W, Feng LJ, Wu Y, Cai Y, Li Z, Zhu X, Liu P, Wan Y, Ke H, Luo HB..  (2014)  Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.,  57  (24): [PMID:25432025] [10.1021/jm500836h]

2. Zhang P, Jiang MY, Le ML, Zhang B, Zhou Q, Wu Y, Zhang C, Luo HB..  (2020)  Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.,  30  (14): [PMID:32527553] [10.1016/j.bmcl.2020.127254]

3. Xi M, Sun T, Chai S, Xie M, Chen S, Deng L, Du K, Shen R, Sun H..  (2022)  Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,  232  [PMID:35144038] [10.1016/j.ejmech.2022.114170]

Source

Source(1):

• Scientific Literature